Draft guidance from the FDA on the naming of biosimilars recommends the generic name is retained with four random letters added at the end to provide a unique identifier. “Our current thinking is that shared nonproprietary names are not appropriate for all biological products,” the FDA said in a statement. “There is a need to clearly ...
FDA proposes naming system for biosimilars
By Nicola Garrett
2 Sep 2015